(CercleFinance.com) – Sanofi announces that the New England Journal of Medicine has published the positive results of a phase II trial showing that frexalimab significantly slowed disease activity in people suffering from sclerosis. relapsing-remitting plaque (MS).
The study shows a reduction of 89% and 79% in the appearance of new T1 lesions enhanced by gadolinium, respectively in the group treated with the highest dose and in the group treated with the lowest dose, compared to placebo ─ which corresponded to the primary endpoint.
The results also show that the two doses of frexalimab achieved a significant reduction in T2 lesions.
According to Dr. Patrick Vermersch, Ph.D., of the University of Lille, these results represent ‘important data not only for the potential treatment of multiple sclerosis, but also for the entire multiple sclerosis community. plates’.
‘It should be noted that at week 12, both doses of frexalimab studied achieved a pronounced reduction in new lesions […] and their effect was maintained well over time, especially in the group of patients treated with the highest dose of frexalimab,’ he added.
Sanofi also reports having launched phase III clinical trials on frexalimab in the treatment of relapsing-remitting MS and non-relapsing secondary progressive MS.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information on SANOFI in real time: